Expired activity
Please go to the PowerPak homepage and select a course.

Crafting the New Treatment Mix in CLL: Pharmacist Insights on Delivering Effective Care With Targeted Therapy

This activity is sponsored by PVI, PeerView Institute for Medical Education.

This activity is supported by independent educational grants from AstraZeneca, BeiGene, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Lilly.


March 31, 2023


April 29, 2024

Time to Complete Activity

60 minutes


Enduring Material

Activity Description

Are you prepared to implement advances with targeted agents in CLL in your pharmacy practice? Find out by viewing this “Pharmacy MasterClass & Case Forum” program, recorded during the 2023 Hematology/Oncology Pharmacy Association (HOPA) 19th Annual Conference. Throughout, expert pharmacists will present state-of-the-art evidence supporting the use of highly efficacious targeted strategies in CLL, including covalent and non-covalent BTK inhibitors, BCL2 inhibitors, and chemo-sparing combinations, and give insights on how to apply the evidence supporting these strategies to real-world practice. The experts will also prepare you to anticipate and manage adverse events; proactively address drug interaction and dosing complexities; and provide staff and patient education on single-agent and combination strategies. Don’t miss this opportunity to get the latest on the new treatment mix in CLL!

Target Audience

This activity has been designed to meet the educational needs of hematology-oncology pharmacists, pharmacy managers, and other clinicians involved in the management of CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the mechanistic and pharmacokinetic profiles, and safety/efficacy evidence supporting the treatment roles of novel BTK and BCL-2 inhibitor approaches in CLL
  • Develop pharmacy-guided plans to optimize the integration of novel and emerging BTK and BCL-2 inhibitor strategies into personalized management plans for patients with TN and RR CLL
  • Work collaboratively to address practical aspects of team-based care with targeted therapies in CLL, including care coordination, drug-drug interactions, patient counseling, staff education, and safety and dosing considerations

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Emily K. Dotson, PharmD, BCOP
Inpatient Clinical Manager
Clinical Pharmacist Specialist - Hematology
The James Cancer Hospital
Columbus, Ohio

Emily K. Dotson, PharmD, BCOP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; BeiGene; and Janssen Pharmaceuticals, Inc.

Peter Campbell, PharmD, MBA, BCOP
Clinical Pharmacy Manager Lead
NewYork-Presbyterian Hospital, Columbia University Irving Medical Center
Program Director, PGY2 Oncology Pharmacy Residency
NewYork-Presbyterian Hospital
New York, New York

Peter Campbell, PharmD, MBA, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Sarah E. Stump, PharmD, BCPS, BCOP
Clinical Pharmacy Specialist – Adult Malignant Hematology
Vanderbilt University Medical Center
Nashville, Tennessee

Sarah E. Stump, PharmD, BCPS, BCOP, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation Statement

JAPIn support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-012-H01-P
Type of Activity: Application

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

Participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the posttest and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded.  If you successfully complete the posttest (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView